Fig. 1From: Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors a Flow diagram showing subgroups of patients according to the detection of BRAF V600mut ctDNA after treatment initiation. b Flow diagram showing subgroups of patients according to the evolution of BRAF V600mut ctDNA in relation to disease progression. Pts patientsBack to article page